Nɛ-acetyl lysine derivatives with zinc binding groups as novel HDAC inhibitors

HDAC inhibitors have been developed very rapidly in clinical trials and even in approvals for treating several cancers. However, there are few reported HDAC inhibitors designed from Nε-acetyl lysine. In current study, we raised a novel design, which is about Nε-acetyl lysine analogues containing amide acetyl groups with the hybridization of ZBG groups as novel HDAC inhibitors.